Polypill Strategy in Secondary Cardiovascular Prevention

• Published in: The New England journal of medicine Vol. 387; no. 11; pp. 967 - 977
• Main Authors: Castellano, Jose M., Pocock, Stuart J., Bhatt, Deepak L., Quesada, Antonio J., Owen, Ruth, Fernandez-Ortiz, Antonio, Sanchez, Pedro L., Marin Ortuño, Francisco, Vazquez Rodriguez, Jose M., Domingo-Fernández, Alexandra, Lozano, Iñigo, Roncaglioni, Maria C., Baviera, Marta, Foresta, Andreana, Ojeda-Fernandez, Luisa, Colivicchi, Furio, Di Fusco, Stefania A., Doehner, Wolfram, Meyer, Antje, Schiele, François, Ecarnot, Fiona, Linhart, Aleš, Lubanda, Jean-Claude, Barczi, Gyorgy, Merkely, Bela, Ponikowski, Piotr, Kasprzak, Marta, Fernandez Alvira, Juan M., Andres, Vicente, Bueno, Hector, Collier, Timothy, Van de Werf, Frans, Perel, Pablo, Rodriguez-Manero, Moises, Alonso Garcia, Angeles, Proietti, Marco, Schoos, Mikkel M., Simon, Tabassome, Fernandez Ferro, Jose, Lopez, Nicolas, Beghi, Ettore, Bejot, Yannick, Vivas, David, Cordero, Alberto, Ibañez, Borja, Fuster, Valentin
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 15-09-2022
• Subjects: Angiotensin; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Aspirin; Aspirin - adverse effects; Aspirin - therapeutic use; Atorvastatin; Atorvastatin - adverse effects; Atorvastatin - therapeutic use; Blood pressure; Cardiology; Cardiology General; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Cerebral infarction; Clinical Medicine; Confidence intervals; Coronary Disease; Death; Diabetes; Disease prevention; Drug dosages; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Ischemia; Ischemic Stroke - prevention & control; Myocardial Infarction; Myocardial Infarction - complications; Myocardial Infarction - prevention & control; Myocardial Infarction - therapy; Outpatient-Based Clinical Medicine; Patient compliance; Patients; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Polypharmacy; Prevention; Ramipril - adverse effects; Ramipril - therapeutic use; Secondary Prevention - methods; Stroke
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2208275

Among patients with recent MI, therapy with a polypill containing aspirin, ramipril, and atorvastatin led to a lower incidence of major adverse cardiovascular events at a median of 3 years than usual care.